Recursion Pharmaceuticals (RXRX) Rallies 8.7% on Hypophosphatasia

Recursion Pharmaceuticals (RXRX) saw an 8.7% rally to $5.36 after acquiring a $25-million interest in REV102 for hypophosphatasia treatment. Rallybio will receive $7.5 million upfront, $12.5 million for preclinical studies, and $5 million for Phase 1 dosing. They will also earn royalties on future sales and program sale payments.

Rallybio CEO Stephen Uden praised the collaboration with Recursion, calling their joint efforts the first potential oral disease-modifying treatment for hypophosphatasia. While RXRX shows investment potential, other AI stocks may offer higher returns with less risk. Interested investors can explore further in their free report on the best short-term AI stock.

Read more at Yahoo Finance: Recursion Pharmaceuticals (RXRX) Rallies 8.7% on Hypophosphatasia